

ASX Release

Anatara Reports Second Successful Detach™ Trial

Key points:

- Anatara's Detach™ reduced the number of pigs with scour by 41%
- Detach™ reduced the severity of scour by 45%
- Positive results now confirmed in two age groups of piglets; suckers (unweaned) as well as weaner piglets, in two geographical regions
- Data consistent with earlier registration trials on commercial pig farms and supports Anatara's plan to re-register and launch Detach™ in Australia
- Appointment of Dr Trish Holyoake, an experienced pig veterinarian, as clinical trial advisor

BRISBANE, 16 September 2015: Anatara Lifesciences (ASX:ANR) is pleased to announce positive results from its latest Australian field trial of Detach™, a non-antibiotic natural therapy to prevent and treat diarrhoea (also known as scour) in piglets. Anatara is also pleased to announce the appointment of Dr Trish Holyoake, a key advisor to its clinical program.

The trial showed that Detach™ reduced the number of pigs with scour by 41% and reduced the severity of scour by 45%.

Anatara Chief Executive Dr Paul Schober said: "These results reinforce our earlier successful field trial results."

"Anatara is now focusing on completing a third and final field trial to support an application to register Detach™ with the Australian Pesticides and Veterinary Medicines Authority," he said. "We are also scaling up our efforts to register Detach™ in Europe and the US."

Field Trial Overview

This trial was conducted in weaner piglets on a commercial pig farm in South Eastern Queensland. The farm had a history of post-weaning disease caused by *Escherichia coli*.

The study was a blinded, controlled, randomised field trial comparing two parallel groups of piglets.

Group 1 piglets (n=280: 14 piglets per pen) received a placebo at weaning (21 days of age).

Group 2 piglets (n=280: 14 piglets per pen) were administered Detach™ at weaning (21 days of age).

The incidence and severity of scour was determined daily using a scoring system, where 0 = no scour, 1 = loose, semi liquid scour, and 2 = profuse and watery scour.



Results

Despite the history of problems on this farm, there was a low incidence of scour and deaths during the trial period. In the control group, there were two piglets that died (unknown causes) and two piglets that were removed from their pen due to ill-thrift (Total n=4). In contrast, there were no deaths or removals due to ill-thrift in the Detach™ treated group (Total n=0).

The frequency of scour in the control group was 152 (the total number of pigs with scour per pen recorded during the trial), while the frequency of scour in the Detach™ treated group was 89, a 41% reduction ($p<0.02$).

Of the scour recorded, there were 21 occurrences of watery (or severe) scour in the control group, compared with seven in the Detach™ treated group.

Detach™ also significantly reduced the severity of scour (frequency of Score 1 (pasty scour) plus 2 (severe) by 45% (Score 96, Detach vs 173, control; $p<0.02$).

The appropriate statistical analysis was determined and applied by an independent biometrician.

There was a small improvement in the final weight and average daily gain (ADG) from weaning to 28 days post-weaning in the piglets treated with Detach™ of 1%, although the difference was not statistically significant. In the Detach™ treated group, the ADG was 252.1 ± 25.35 g (mean $\pm$ SD; median, 258.42) and in the control group was 249.6 ± 26.3 g (median; 247.9 g).

No antibiotics were administered to piglets to control scour for the duration of this study because of the higher than expected health status of the herd. Microbiological assessment of rectal swabs taken from 40 pigs confirmed the presence of haemolytic (pathogenic) *Escherichia coli* in nine animals.

Anatara Chief Scientific Officer Dr Tracey Mynott said: “Detach™ showed a significant clinical benefit despite the lower than anticipated incidence of scour in this study. Together with the first sucker trial, Detach™ has been shown to be effective in two different age groups of piglets (weaners and suckers), in two major pig producing areas in different geographical areas (Northern Victoria and South East Queensland) and under two different clinical scenarios (extreme diarrhoea and death in Victoria, as well as mild conditions in Queensland). These results are consistent with findings from our earlier registration trials”.

Subject to a successful third field trial and regulatory approval, Anatara remains on track to launch Detach™ in Australia in 2016.

Pork CRC Chief Executive, Dr Roger Campbell said “the latest results confirm our decision to work with Anatara to pursue Detach™ as an alternative to antibiotics for control of diarrhoea in young pigs”.

“The results are typical of what we see with post-weaning scour. It can be severe or mild but it always has been and always will be present in the industry. Given the increasing global pressure to reduce antibiotic use and resistance in animal agriculture Anatara’s technology would seem to have a role in helping achieve these objectives. We are encouraged by the latest results”, he said.

New Appointment

Anatara is also pleased to announce the appointment of Dr Trish Holyoake, as a technical advisor on a part-time basis. Until recently, Dr Holyoake was Principal Veterinary Officer with the Pig Services Centre, Department of Economic Development, Jobs, Transport and Resources, Victoria. Dr Holyoake also holds academic appointments and lectures on pig health and production and has published extensively. Dr Holyoake has a degree in veterinary science as well as a PhD from the University of Melbourne and is a member of several Australian and international pig industry bodies.

Anatara Chairman Dr Mel Bridges said; “We are pleased that Dr Holyoake, a well-regarded animal health expert has joined the Anatara team. We are also delighted that the latest Detach™ field trial reinforces earlier results. This is an important milestone for Anatara and validates our belief that Detach™ will become a valuable non-antibiotic tool for farmers to produce healthy pigs.”

For more information please contact:

General inquiries Mel Bridges Chairman, Anatara Lifesciences +61 (0) 413 051 600 melbridges@parmacorp.com	Media inquiries Gavin Lower Buchan Consulting +61 (0)3 8866 1215 glower@buchanwe.com.au
--	--

About Anatara Lifesciences

Anatara Lifesciences is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach™ is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.